Abstract:453 Background: More than 70% of hepatocellular carcinoma (HCC) patients are in the intermediate or advanced stages at the time of diagnosis. TACE, TKI and PD-1 antibody are all recommended for patients with unresectable HCC (uHCC) according to Chinese HCC guidelines. There are few scientific trials to back up the safety and effecacy of TACE+TKI+PD-1 antibody for the treatment of uHCC and conversion resection. In this study, we explored the safety and efficacy of the TACE+TKI+PD-1 antibody in uHCC. Methods: This is a prospective, multicenter, cohort study (NCT04997850). Key Eligibility Criteria:18 years old ≤ age ≤ 70 years old; HCC confirmed by histopathology or cytology; No systemic treatment history. ECOG PS score 0-1; Child-Pugh A/B; BCLC stage B/C.Experience group: TACE + Lenvatinib (12mg when≥ 60kg/8mg when < 60kg QD) + Camrelizumab/ Sintilimab (200 mg ivgtt Q3W);Control group: TACE. Results: From Sep 2020 to May 2021, 38 patients were enrolled in experimental group (Table). At the cutoff date (Sep 10 2021), the median follow-up was of 33.34 weeks (Table). The conversion resection rate was 50% (19/38), and the conversion success rate was 52.6% (20/38). Among the 19 patients, 5 cases achieved complete pathological response and 1 case achieved major pathological response. The 48 weeks' OS rate and PFS were 96.4% (95%CI 92.9% to 99.9%) and 91.7%(95%CI 85.8% to 97.4%).22 patients had level 3 treatment related adverse events (TRAE), there were no level 4 and 5 TRAEs. At the last follow-up, the ORR rate based on mRECIST was 84.2%, and the DCR rate was 94.7% (Table). Conclusions: TACE + Lenvatinib + PD-1 antibody is safe and effective, and conversion resection after the triple-treatment is feasible for uHCC. Clinical trial information: 04997850. Baseline characteristics, adverse events and clinical outcomes (N=38) Baseline Characteristics Gender, male, n (%) 35(92.1%) Bodyweight, kg, median, (range) 62(45-90) Etiology, [HBV/HCV/Non-HBV/HCV, n (%)] 29(76.3%)/1(2.6%)/8(21.1%) ECOG PS, [0/1, n (%)] 36(94.7%)/2(5.3%) AFP level, ng/ml, median(range) 353(0.91-470518) DCPlevel,mAU/mL,median(range) 6274(32-75000) BCLC stage, [B/C, n (%)] 9(23.7%)/29(76.3%) Tumor numbers, [1/2/3, n (%)] 19(50%)/15(39.5%)/4(10.5%) Treatment Related Adverse Events (TRAE), n (%) Any Adverse Events 100(100%) Most common TRAEs(≥50% of patients) Abdominal pain 27(71.1%) Aspartate aminotransferase increased 25(65.8%) Alanine aminotransferase increased 25(65.8%) Hypertension 22(57.9%) ≥Grade 3 TRAEs 22(57.9%) RAE leading to drug reduction 3(7.9%) TRAE leading to drug conclusions 0(0%) Clinical Outcomes mRECIST ORR 32(84.2%) CR/PR/SD/PD 6(15.8%)/26(68.4%)/4(10.5%)/2(5.3%)

Safety and efficacy of transcatheter arterial chemoembolization plus early sequential percutaneous radiofrequency ablation for the treatment of large primary liver cancer with hepatitis B cirrhosis:a single-center experience

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

[Clinical Effect of Terminal Branches Portal Vein Embolization Combined with Transcatheter Arterial Chemoembolization on Liver Neoplasms].

[The Combination of Percutaneous Iohexol-Ethanol Injection with Radiofrequency Ablation for the Treatment of Primary Liver Cancer in High-Risk Locations].

A systematic review and meta-analysis on the efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer

Combination of transcatheter arterial chemoembolization and radiofrequency ablation in hepatocellular carcinoma treatment

High‐intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long‐term efficacy and prognosis of primary liver cancer

Randomized Clinical Trial of Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Intermediate Stage (BCLC Stage B) Hepatocellular Carcinoma Beyond Milan Criteria.

Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation for Liver Malignancy at High-risk ;Locations

Comparison Between Chemoembolization Combined with Radiotherapy and Chemoembolization Alone for Large Hepatocellular Carcinoma

Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma

Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation Delays Tumor Progression and Prolongs Overall Survival in Patients with Intermediate (BCLC B) Hepatocellular Carcinoma.

Efficacy of transcatheter arterial chemoembolization combined with radiofrequency ablation in advanced hepatocellular carcinoma patients

Percutaneous Radiofrequency Ablation Combined With Transarterial Chemoembolization Plus Sorafenib for Large Hepatocellular Carcinoma Invading the Portal Venous System: A Prospective Randomized Study

Comparison of the Efficacy of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation Versus Monotherapy in Patients with Liver Cancer

The Efficacy of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma in a Cohort of 487 Patients

Clinical Application of a Combination Therapy of Percutaneous Radiofrequency and Transcatheter Arterial Chemoembolization in Large Hepatic Tumors

A system evaluation of radiofrequency ablation plus transcatheter hepatic arterial chemoembolization for primary hepatocellular carcinoma

Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma

Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma

The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma.